NIOX Group Plc
CSSPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$378.32M
Close$
$1.89
110.5% upside
Current Fair Value
110.5% upsideUndervalued by 110.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $378.32 Million |
|---|---|
| Enterprise Value | $362.22 Million |
| Annual dividend | $0.02 |
| Dividend yield | 2.25% |
| Earnings per Share | $0.02 |
| Beta | -0.09 |
| Outstanding Shares | 419,161,143 |
Return
| Return on Equity | 18.46% |
|---|---|
| Return on Assets | 16.69% |
| Return on Invested Capital | 30.02% |
Valuation & Multiples
| P/E Ratio | 41.2 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.87 |
| Enterprise Value to EBIT | 18.2 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 29, 2026
EPS Estimate
$0.02
Consensus analyst estimateRevenue Estimate
$31.82 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 23, 2027
EPS Estimate
$0.01
Consensus analyst estimateRevenue Estimate
$35.61 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About NIOX Group Plc
97 employees
CEO: Jonathan Charles Emms
Niox Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis and management of asthma. It offers NIOX VERO, a non-invasive point-of-care system that provides fractional exhaled nitric oxid...